What You Should Know:
– Quris-AI, a leading Bio-AI company revolutionizing drug development, has acquired Nortis, a pioneer in microphysiology systems (MPS) technology, formerly known as Numa Biosciences.
– The strategic acquisition will integrate Nortis’s advanced Kidney-on-Chip technology into Quris-AI’s Bio-AI platform, enhancing its ability to predict drug safety and efficacy in humans.
Combining Cutting-Edge Technologies
Nortis’s Kidney-on-Chip models have been validated by the National Center for Advancing Translational Sciences (NCATS) and represent a significant advancement in in-vitro drug testing and personalized medicine. By combining this technology with Quris-AI’s machine learning models and patented patient-on-chip system, the company aims to improve the accuracy and efficiency of drug development.
Quris-AI’s Bio-AI Platform: Revolutionizing Drug Development
Quris-AI’s Bio-AI Clinical Prediction Platform is transforming the drug development process by simulating clinical trials and predicting drug responses in humans. This approach reduces the reliance on traditional animal testing and accelerates the identification of promising drug candidates.
The acquisition of Nortis will enable Quris-AI to:
- Enhance its Bio-AI Platform: Integrate Nortis’s Kidney-on-Chip technology to improve the accuracy of drug safety and efficacy predictions.
- Advance Drug Development: Accelerate the development of new drugs by identifying and eliminating potentially harmful candidates earlier in the process.
- Expand Research Collaborations: Continue Nortis’s collaborations with research institutes, the FDA, and pharmaceutical companies to advance kidney disease research.
- Improve Drug Safety Prediction: Strengthen Quris-AI’s capabilities in predicting drug safety and efficacy in humans.
“We are thrilled to incorporate Nortis’s pioneering technology into the Quris-AI platform,” said Dr. Isaac Bentwich, Founder and CEO of Quris-AI. “This acquisition represents a powerful synergy between Nortis’s legacy of scientific excellence and Quris’s cutting-edge Bio-AI capabilities to significantly enhance the accuracy of drug safety predictions in both pre-clinical and clinical phases. We are dedicated to continuing to push the boundaries of drug safety prediction and personalized medicine, ultimately leading to better patient outcomes and advancing the future of healthcare.”
